Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 5/20 | 0.42 |
| ▸ | AR | P10275 | 3/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.39 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.36 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9889490 | 0.87 | SLC22A12 (0.41) | XDHARSCN9ASLC22A12 | |
| SCHEMBL875188 | 0.85 | XDH (0.42) | XDHARSCN9AS1PR1SLC22A12 | |
| SCHEMBL17460303 | 0.85 | AR (0.41) | XDHARSCN9AS1PR1IKBKE | |
| SCHEMBL30997487 | 0.81 | L3MBTL1 (0.50) | ARSCN9AS1PR1 | |
| SCHEMBL875974 | 0.81 | L3MBTL1 (0.50) | ARSCN9AS1PR1 | |
| SCHEMBL17460250 | 0.81 | AR (0.42) | XDHARSCN9AS1PR1IKBKE | |
| SCHEMBL15832084 | 0.79 | AR (0.48) | XDHARSCN9AS1PR1SLC22A12 | |
| SCHEMBL875366 | 0.77 | AR (0.49) | XDHARSCN9ASLC22A12IKBKE | |
| SCHEMBL9889488 | 0.77 | S1PR3 (0.44) | XDHSCN9AS1PR1SLC22A12 | |
| SCHEMBL10054035 | 0.76 | MAP4K4 (0.48) | ARSCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174968-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-11-03 | — | — | US | disclosed |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2015-04-09 | — | — | US | disclosed |
| US-8637536-B2 | Pyrimidinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 | GLAXO GROUP LIMITED (GB) | 2014-01-28 | — | — | US | disclosed |
| US-20130252963-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 | GLAXO GROUP LIMITED (GB) | 2013-09-26 | — | — | US | disclosed |
| US-20120142717-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142717-A1 | COMPOUNDS | LIPG, PLA2G1B, ENPP2 | XDH 2208/4885AR 4068/4885SCN9A 4224/4885 |
| US-20130252963-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASE OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | XDH 1014/4885AR 3287/4885SCN9A 4695/4885 |
| US-20150099756-A1 | PYRIMIDINONE COMPOUNDS FOR USE IN THE TREATMENT OF DISEASES OR CONDITIONS MEDIATED BY LP-PLA2 | PLA2G1B, PLA2G4A, PLA2G4B | XDH 986/4885AR 3324/4885SCN9A 4668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.